Market Cap (In USD)
37.32 Million
Revenue (In USD)
-
Net Income (In USD)
-64.73 Million
Avg. Volume
126.1 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.87-22.22
- PE
- -0.72
- EPS
- -1.72
- Beta Value
- -0.223
- ISIN
- US0373261058
- CUSIP
- 037326105
- CIK
- 1880438
- Shares
- 30098720.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Eric E. Easom
- Employee Count
- -
- Website
- https://www.an2therapeutics.com
- Ipo Date
- 2022-03-25
- Details
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
More Stocks
-
098460Koh Young Technology Inc.
098460
-
STGX
-
603909
-
1546
-
ZNNCZann Corp.
ZNNC
-
LCUT
-
KITT
-
011200HMM Co.,Ltd
011200